Pooled results indicated that the <i>MTRR</i> A66G</span> polymorphism was associated with an increased overall cancer</span> risk (homozygous model: OR = 1.08, 95% CI = 1.02-1.15, <i>P</i> = 0.009; recessive model: OR = 1.06, 95% CI = 1.00-1.12, <i>P</i> < 0.001 and allele comparison: OR = 1.03, 95% CI = 1.00-1.06, <i>P</i> < 0.001).
The MTRR A66G (rs1801394) polymorphism is found to be associated with decreased enzyme affinity for MTR, the gene that encodes MS, and has been widely investigated for cancer risk, including leukemia.
Methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) play an essential role in both DNA synthesis and methylation and polymorphisms in the MTHFR gene, 677C>T, 1298A>C and the MTRR gene, 66A>G, are associated with several types of malignancy.